Core Viewpoint - Theravance Biopharma reported its financial and operational results for Q1 2025, highlighting growth in YUPELRI sales and advancements in clinical trials for ampreloxetine, while also addressing ongoing strategic reviews to enhance shareholder value [1][2][8]. Financial Performance - Total revenue for Q1 2025 was $15.4 million, entirely from Viatris collaboration revenue, which increased by $0.9 million, or 6%, compared to Q1 2024 [4][29]. - YUPELRI net sales reached $58.3 million, reflecting a 6% increase year-over-year [5][6]. - The company reported a net loss of $13.6 million for Q1 2025, compared to a net loss of $11.7 million in Q1 2024 [13][29]. Operational Highlights - The CYPRESS study for ampreloxetine is nearing completion, with final patient enrollment expected by late summer 2025 [5][6]. - Customer demand for YUPELRI grew by 5% in Q1 2025, with doses pulled through the hospital channel increasing by 48% year-over-year [6][5]. - The company presented data at the American Academy of Neurology 2025 Annual Meeting, showcasing the pharmacodynamic effects of ampreloxetine [6]. Strategic Initiatives - A Strategic Review Committee has been formed to evaluate alternatives aimed at unlocking shareholder value [8]. - The company continues to expect full-year 2025 R&D expenses between $32 million and $38 million, and SG&A expenses between $50 million and $60 million [14]. Market Context - Ampreloxetine is being developed for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), with potential for significant clinical benefits [15][19]. - There are approximately 50,000 MSA patients in the US, with 70-90% experiencing nOH symptoms, indicating a substantial unmet medical need [17][18].

Core Insights - Theravance Biopharma announced the presentation of analyses from the initial Phase 3 program of ampreloxetine at the International MSA Congress, highlighting its potential to address neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) [1][2] - The ongoing registrational study (CYPRESS) aims to evaluate the efficacy and durability of ampreloxetine in treating symptomatic nOH in MSA patients [4][5] Company Overview - Theravance Biopharma focuses on developing innovative therapies, with ampreloxetine being a late-stage investigational norepinephrine reuptake inhibitor for symptomatic nOH in MSA patients [3][10] - The company has received Orphan Drug Designation for ampreloxetine in the US, indicating its commitment to addressing unmet medical needs in rare diseases [3] Clinical Study Details - The CYPRESS study is a multi-center, randomized withdrawal trial evaluating ampreloxetine's efficacy after 20 weeks of treatment, with the primary endpoint being the change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score [4] - Previous studies (Study 0169 and Study 0170) assessed the efficacy and safety of ampreloxetine, with Study 0170 showing a significant benefit in MSA patients, indicated by a 72% reduction in treatment failure odds compared to placebo [5][7] Disease Context - Multiple system atrophy (MSA) is a progressive disorder affecting movement and autonomic functions, with approximately 50,000 patients in the US, of which 70-90% experience nOH symptoms [8][9] - Neurogenic orthostatic hypotension (nOH) is characterized by a significant drop in blood pressure upon standing, leading to debilitating symptoms such as dizziness and fainting [9]

Company Overview - Theravance Biopharma, Inc. focuses on delivering innovative medicines that improve patients' lives, leveraging decades of expertise in the biopharmaceutical industry [3] - The company has developed the FDA-approved YUPELRI® (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD) [3] - Ampreloxetine, a late-stage investigational drug, is being developed for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), with potential to be a first-in-class therapy [3] Upcoming Financial Results - Theravance Biopharma will report its first quarter 2025 financial results and provide a business update on May 8, 2025, after market close [1] - A conference call and webcast will be held on the same day at 5:00 pm EDT [1][2] Conference Call Participation - Participants can join the live call by dialing (800) 715-9871 from the US or (646) 307-1963 for international callers, using Conference ID 3369474 [2] - The conference call will also be available for live streaming on Theravance Biopharma's website [2] - A replay of the webcast will be accessible for 30 days until June 7, 2025 [2]

It has been about a month since the last earnings report for Theravance Biopharma (TBPH) . Shares have added about 0.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Theravance Bio due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since ...

Financial Performance - Theravance Biopharma reported a fourth-quarter 2024 adjusted net loss of 5 cents per share, consistent with the Zacks Consensus Estimate, compared to earnings of 3 cents per share in the same quarter last year [1] - Total revenues for the quarter were $18.8 million, slightly exceeding the Zacks Consensus Estimate of $18.0 million, and reflecting a year-over-year increase of 6.8% due to higher collaboration revenues from partner Viatris [3] - The reported loss, including share-based compensation, income tax expense, and non-cash interest expense, was 31 cents per share, compared to a loss of 17 cents in the year-ago quarter [2] Collaboration and Revenue Sources - The revenue was entirely derived from Viatris' collaboration revenues related to Yupelri (revefenacin) sales, which increased by 8% year over year in the fourth quarter [4] - Viatris recorded U.S. net sales of Yupelri at $66.7 million, marking a 10% year-over-year increase [6] - Viatris retains 65% of the profits from Yupelri sales, while Theravance receives 35%, which includes its share of net sales and proportionate costs [5] Expenses and Financial Guidance - Research and development expenses (excluding share-based compensation) totaled $8.1 million, up nearly 23% from the previous year, while selling, general, and administrative expenses increased around 23% year over year to $14.1 million [9] - For 2025, Theravance expects adjusted R&D expenses to be in the range of $32-$38 million and adjusted SG&A expenses between $50 million and $60 million, with share-based compensation expenses projected at $18-$20 million [12] Cash Position and Future Outlook - As of December 31, 2024, Theravance had cash, cash equivalents, and marketable securities amounting to $88.4 million, down from $91.4 million as of September 30, 2024 [11] - The company anticipates adjusted losses and cash burn in 2025 to be similar to 2024 levels, with an adjusted loss of $16 million and cash burn of $14 million recorded in 2024 [13] Pipeline Developments - Theravance is developing ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor for treating neurogenic orthostatic hypotension in patients with multiple system atrophy [14] - The phase III CYPRESS study for ampreloxetine was initiated in 2024, with patient enrollment expected to complete by mid-2025, and top-line data anticipated six months post-enrollment [15]

Financial Data and Key Metrics Changes - In Q4 2024, YUPELRI net sales increased by 10% year-over-year, reaching $66.7 million, marking an all-time high [4] - Full year YUPELRI sales totaled $239 million, with an 8% increase in net sales for 2024 and an 11% growth in demand [11][14] - Collaboration revenue grew by 8% to approximately $19 million in Q4 [32] - Operating expenses, excluding share-based compensation, increased to $22 million due to higher commercial and medical affairs spending [32] Business Line Data and Key Metrics Changes - YUPELRI's hospital performance saw doses increase by 49% year-over-year, with 285,000 redoses pulled through to hospital customers [4][13] - The hospital business accounts for roughly 10% of total YUPELRI volume, with 90% coming from community settings [77] - Ample enrollment in the CYPRESS study for ampreloxetine is on track, with expectations for expedited NDA filing [5][20] Market Data and Key Metrics Changes - TRELEGY reported full year sales of $3.5 billion, up 26% year-over-year, triggering a $50 million milestone payment [15] - The company anticipates achieving an additional $150 million in milestones from TRELEGY in 2025 and 2026 [16] Company Strategy and Development Direction - The company aims to grow YUPELRI revenue while increasing brand profitability, with potential near-term sales milestones in the U.S. and royalties from China [7] - For ampreloxetine, the focus is on completing enrollment in the CYPRESS study and preparing for an expedited NDA filing [8] - The company is committed to maximizing the value of TRELEGY and returning excess capital to shareholders [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the financial position entering 2025, with $88 million in cash and no debt [39] - The company is focused on driving YUPELRI growth through strong demand generation and a patient-centered strategy [40] - Management highlighted the potential impact of ampreloxetine on patients with MSA suffering from nOH symptoms [41] Other Important Information - The company completed market research indicating a significant unmet need for better nOH therapies, with over 70% of surveyed neurologists agreeing [25] - The target product profile for ampreloxetine aligns with physician preferences, suggesting a favorable outlook if approved [28] Q&A Session Summary Question: What drove the success in the hospital channel this quarter? - The success was attributed to effective execution of strategy and wins in larger systems, with therapeutic interchange contributing to increased volume [45][46] Question: What is the trend for the hospital performance into 2025? - Q1 is typically softer, but there is a demonstrated need for YUPELRI, which may provide a tailwind [60] Question: What are the next steps for YUPELRI in China? - The company is waiting for regulatory feedback from Viatris, with a typical two-year window expected from submission to approval [62] Question: What was the nature of the recent FDA feedback on ampreloxetine? - The feedback was from a Type C meeting to clarify filing content and ensure alignment on key requirements for full approval [67] Question: What percentage of YUPELRI sales are non-hospital sales? - The hospital business accounts for roughly 10% of total YUPELRI volume, with the community setting making up the majority [77] Question: What is the bar for success for the CYPRESS readout? - A one-point change in the OHSA composite score is considered clinically meaningful for success [88]

分组1 - Theravance Biopharma reported a quarterly loss of $0.05 per share, consistent with the Zacks Consensus Estimate, compared to earnings of $0.03 per share a year ago [1] - The company posted revenues of $18.75 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 3.50% and up from $17.57 million year-over-year [2] - Over the last four quarters, Theravance Biopharma has surpassed consensus EPS estimates two times and revenue estimates two times [2][1] 分组2 - The stock has underperformed, losing about 4.7% since the beginning of the year, while the S&P 500 gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $17.65 million, and for the current fiscal year, it is $0.84 on revenues of $111.23 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 50% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Theravance Biopharma, Inc. is set to report its fourth quarter and full year 2024 financial results on February 26, 2025, along with a business update [1] Company Overview - Theravance Biopharma focuses on delivering impactful medicines, leveraging decades of expertise [3] - The company has developed the FDA-approved YUPELRI® (revefenacin) inhalation solution for chronic obstructive pulmonary disease (COPD) [3] - Ampreloxetine, a late-stage investigational drug, is being developed for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA) [3] - The company aims to create and drive shareholder value [3]